Table 3. Univariate and multivariate Cox proportional hazard analyses predicting factors for CVR.

Characteristics	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Age, years	1.000	0.987–1.013	0.985
Sex, male	0.857	0.625–1.174	0.336
Cirrhosis	0.788	0.581–1.070	0.127
TDF combination therapy vs. TDF monotherapy	0.937	0.685–1.282	0.686
Treatment status
NA-naïve vs. NA-experienced	1.128	0.833–1.527	0.437
LAM-R vs. NA-naïve	1.075	0.725–1.593	0.719
ADV-R vs. NA-naïve	0.517	0.247–1.082	0.080	0.436	0.205–0.925	0.031
MDR vs. NA-naïve	0.812	0.550–1.198	0.294	0.556	0.361–0.855	0.008
Suboptimal group 1a vs. NA-naïve	1.014	0.521–1.973	0.967
Suboptimal group 2b vs. NA-naïve	0.935	0.548–1.596	0.806
Initial ALT, IU/L	1.000	0.999–1.001	0.990
Initial HBV-DNA, log IU/mL	0.711	0.652–0.775	< 0.001	0.718	0.658–0.783	< 0.001
HBeAg-positive status	0.639	0.472–0.864	0.004	0.730	0.539–0.988	0.041

^aPrior suboptimal response to LAM or ADV or LAM + ADV.

^bPrior suboptimal response to ETV.

CVR, complete virological response; HR, hazard ratio; CI, confidence interval; TDF, tenofovir disoproxil fumarate; NA, nucleos(t)ide analogue; LAM, lamivudine; R, resistant; ADV, adefovir; MDR, multidrug-resistant; ALT, alanine aminotransferase; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ETV, entecavir.